衰弱与喉鳞状细胞癌患者的生存结局
该回顾性研究纳入苏格兰西部2014至2020年诊断的867例喉鳞状细胞癌患者,采用改良五项衰弱指数(mFI-5)评估衰弱程度。结果显示78%(n=676)的患者存在衰弱,不衰弱者中位生存期为78个月,重度衰弱者为23个月;姑息治疗组总生存结局较根治性治疗组更差(HR=7.96,p<0.001)。
要点
- 78%(n=676)的喉鳞状细胞癌患者存在衰弱。
- 不衰弱者中位生存期78个月,重度衰弱者23个月。
- 姑息治疗组总生存较根治性治疗组差(HR=7.96,p<0.001)。
核心结论
- 本研究表明衰弱在喉鳞状细胞癌患者中常见,并导致更差的死亡率和生存结局。
研究设计与样本
- 回顾性数据收集,纳入苏格兰西部2014年至2020年诊断的喉鳞状细胞癌患者。
- 采用改良五项衰弱指数(mFI-5)测量衰弱并按衰弱程度对患者分类。
- 统计分析采用Mann-Whitney U检验或方差分析比较均值差异,并采用生存分析评估总生存时间。
主要发现
- 共纳入867例患者,其中78%(n=676)被判定为衰弱。
- 不衰弱患者中位生存期为78个月,重度衰弱患者为23个月。
- 姑息治疗组总生存结局较根治性治疗组更差(HR=7.96,p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty increases the risk of mortality in the head and neck cancer population. This study examines the association between frailty and survival outcomes in patients with laryngeal squamous cell cancer (LSCC). METHOD: Retrospective data collection from patients in the West of Scotland diagnosed with LSCC between 2014 and 2020. The Modified Five Item Frailty Index (mFI-5) measures frailty and categorizes patients according to their level of frailty. Statistical tests used were the Mann-Whitney U-test or ANOVA for differences in means and survival analyses for overall survival time. RESULTS: There were 867 patients included. Seventy-eight percent (n = 676) of patients were deemed frail. Median survival for "not frail" patients was 78 months and "severely frail" was 23 months. The palliative treatment group had worse overall survival outcomes compared to curative (hazard ratio (HR) of 7.96, p < 0.001). CONCLUSION: This study demonstrates frailty is common in patients with LSCC and leads to worse mortality and survival outcomes.
引用
- McCann C, Hurley R, McGovern J, et al. Frailty and the Survival Outcomes of Patients With Laryngeal Squamous Cell Cancer. Head Neck. 2024. PMID: 39578701. doi:10.1002/hed.27951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。